Sophiris Bio
Protox Therapeutics Changes Name to Sophiris Bio
Monday, April 02, 2012
SAN DIEGO, CA AND VANCOUVER, April 2, 2012/CNW/ - Protox Therapeutics Inc. (TSX: PRX) announced that it has changed its name to Sophiris Bio, Inc. effective today, and the symbol "SHS" has been reserved for its use on the TorontoStock Exchange. Trading under the new ticker symbol "SHS" is expected to commence on or about April 5, 2012.
The change is part of an operational realignment that began in 2011 led by Executive Chairman and President Lars Ekman, M.D., Ph.D., to focus on the development of a late-stage, highly targeted treatment for benign prostatic hyperplasia (BPH or enlarged prostate), an unsatisfied market with blockbuster potential. Sophiris, located in San Diego, has recruited a management team that has achieved more than twenty drug approvals and expects to initiate pivotal Phase 3 trials for its lead drug candidate for BPH called PRX302 before the end of 2012.
"The science behind Sophiris and PRX302 is biotechnology at its finest, with a novel, highly selective approach for patients with BPH without the unwanted side effects" said Dr. Lars Ekman, Executive Chairman and President of Sophiris.